OTCMKTS:LYRA Lyra Therapeutics Q2 2025 Earnings Results & Report $0.19 0.00 (0.00%) As of 11/6/2026 Lyra Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$5.51 versus the -$5.79 consensus estimate, while revenue of $292 thousand topped the $181 thousand estimate by $111.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call4:00 PM ET Lyra Therapeutics EPS ResultsActual EPS-$5.51Consensus EPS -$5.79Beat/MissBeat by +$0.28One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersLyra Therapeutics Revenue ResultsActual Revenue$292 thousandExpected Revenue$181 thousandBeat/MissBeat by +$111.00 thousandYoY Revenue GrowthN/AUpcoming EarningsLyra Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lyra Therapeutics Q2 2025 Earnings FAQ Did Lyra Therapeutics beat earnings estimates for Q2 2025? Lyra Therapeutics (OTCMKTS:LYRA) reported earnings of -$5.51 per share for Q2 2025, beating the consensus estimate of -$5.79. The report was announced on Tuesday, August 12, 2025. What was Lyra Therapeutics' revenue for Q2 2025? Lyra Therapeutics reported revenue of $292 thousand for Q2 2025, against a consensus estimate of $181 thousand. When is Lyra Therapeutics' next earnings date? Lyra Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lyra Therapeutics on the company's earnings history page. Lyra Therapeutics Earnings HeadlinesLyra Therapeutics Inc.August 29, 2026 | marketwatch.comLyra Therapeutics Ends Major Office Sublease AgreementApril 17, 2026 | tipranks.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 8 at 1:00 AM | Porter & Company (Ad)Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECApril 17, 2026 | globenewswire.comAfter layoffs, Lyra Therapeutics exits Watertown and Waltham leasesApril 14, 2026 | bizjournals.comTreating allergic fungal rhinosinusitis in childrenApril 8, 2026 | msn.comSee More Lyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email. Email Address About Lyra TherapeuticsLyra Therapeutics (OTCMKTS:LYRA) is a biotechnology company focused on developing long-acting, locally administered treatments for diseases of the ear, nose and throat. The company’s programs are designed to deliver medication directly to the nasal passages, with the goal of improving treatment duration, reducing reliance on daily therapies and addressing limitations associated with conventional nasal sprays. Lyra’s technology is based on its proprietary, bioresorbable nasal delivery platform, which is intended to provide controlled drug release over an extended period. Its primary programs included LYR-210, an investigational device designed to deliver mometasone furoate for the treatment of chronic rhinosinusitis, and LYR-220, a later-generation product candidate developed for patients with chronic rhinosinusitis, including those with nasal polyps. Founded in 2005 and headquartered in Waltham, Massachusetts, Lyra has conducted its development activities primarily in the United States. Its lead products remain investigational and have not been established as approved treatments. The company has also evaluated strategic alternatives and reduced its operations following setbacks in clinical development.View Lyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Sandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
